Stanford Liver Transplant Program in San Jose

The Stanford Liver Transplant Program, located in San Jose, California, has been a part of the Multi-Organ Transplant Program since 1991. With a track record of over 800 adult liver transplantations, the program consistently surpasses national patient and liver survival rates at the one and three-year marks post-transplantation. Patients benefit from a comprehensive evaluation process conducted by specialized transplant doctors, who assess medical records and determine necessary tests. The program also offers access to advanced clinical trials for eligible patients, ensuring they receive the latest treatment options available. Generated from the website

The Kidney and Pancreas Transplant Program at Stanford Health Care is recognized as one of the most successful transplant programs in the United States, with a history of pioneering treatment methods since performing California's first kidney transplant in 1960. The program is dedicated to providing personalized evaluation and advanced care for patients with end-stage kidney disease and Type 1 diabetes, ensuring exceptional outcomes and improved quality of life. With a team of highly experienced specialists, the program emphasizes a collaborative approach to treatment, offering individualized attention and access to innovative clinical trials. Their commitment to excellence is further strengthened through partnerships with the Stanford Medicine Institute for Immunity, Transplantation, and Infection, focusing on the latest advancements in transplantation medicine. Generated from the website

Dr. Ahearn is a board-certified nephrologist. He is also a clinical assistant professor in the Stanford University School of Medicine Division of Nephrology.He specializes in providing innovative care to kidney disease and transplant patients. He develops a comprehensive, compassionate care plan personalized to each patient in his care.In addition to his clinical practice, Dr. Ahearn has conducted research on barriers to transplantation for patients with extended dialysis exposure, disparities in living kidney donation, and disparities in access to kidney transplant. He also has researched kidney transplant outcomes as they relate to the timing of dialysis initiation plus new pharmaceuticals for the kidney transplant population.Dr.